Group 1 - UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and a price target of $6 [1] - The company has a potential blockbuster program involving a CD47 combination therapy currently in Phase II for metastatic breast cancer [1] - UBS anticipates ALX reporting a "robust" dataset in mid-2027, showcasing the efficacy of the CD47 inhibitor evorpacept in CD47 high and/or HER2+ metastatic breast cancer patients [1]

Summary of ALX Oncology FY Conference Call (March 03, 2026) Company Overview - **Company**: ALX Oncology (NasdaqGS:ALXO) - **Key Personnel**: Jason Lettmann (CEO), Dr. Barbara Klencke (Chief Medical Officer) - **Focus**: Advancing two novel oncology treatments: evorpacept (EVO) and ALX2004 [2][3] Core Programs Evorpacept (EVO) - **Type**: Novel CD47-targeting therapy - **Development**: In development since 2015, focusing on how cancer evades immune detection via CD47 [2][3] - **Clinical Focus**: - Currently targeting breast cancer, particularly post-HER2 treatment patients [4][5] - ASPEN breast study aims to enroll 80 patients, with top-line data expected in mid-2027 [4][20] - **Clinical Data**: - ASPEN-06 study showed a 65% response rate in HER2-positive patients compared to 26% in the control arm, indicating a 40% delta [10][11] - Combination studies with other therapies (e.g., Herceptin, zanidatamab) have shown promising results [6][10] - **Safety Profile**: No significant on-target toxicities reported, differentiating from conventional CD47 therapies [8][17] ALX2004 - **Type**: EGFR-targeted antibody-drug conjugate (ADC) - **Development**: Focused on minimizing skin toxicity and maximizing therapeutic window [21][22] - **Clinical Trials**: - Ongoing dose escalation studies, with safety data expected in the second half of 2026 [27] - Targeting EGFR overexpressing tumors, including lung, head and neck, colorectal, and esophageal cancers [27] - **Unique Features**: - Utilizes a proprietary linker and TOPO1 payload, aiming for improved efficacy and safety [22][23] Financials - **Recent Financing**: Closed a financing round of $150 million, funding operations through the first half of 2028 [5][30] - **Market Opportunity**: Approximately 20,000 addressable patients in the HER2-positive and CD47 overexpressing population [20] Strategic Outlook - **Execution Focus**: Emphasis on executing clinical studies and achieving pivotal readiness for both programs by the end of 2027 [28][30] - **Partnership Opportunities**: Open to collaborations, with a successful history of partnerships (e.g., with Sanofi) [32][33] - **Market Positioning**: Positioned to address significant unmet needs in oncology, particularly in breast cancer and EGFR-related tumors [28][29] Additional Insights - **Clinical Validation**: The unique mechanism of action of EVO, using a dead Fc to avoid on-target toxicity, has been validated across multiple studies [6][8] - **Response Rates**: High response rates in various cancer settings indicate the potential of both EVO and ALX2004 to change treatment paradigms [10][12][13] - **Future Data**: Upcoming data presentations at major conferences (e.g., ESMO Breast Cancer 2026) are anticipated to further validate the efficacy of these treatments [19][20]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $22.8 million for Q4 2025, or $0.42 per basic undiluted share, compared to a net loss of $29.2 million for Q4 2024, or $0.55 per basic and diluted share, indicating a decrease in year-over-year spending primarily due to lower stock compensation and personnel costs [26][24]. Business Line Data and Key Metrics Changes - The clinical development of Evorpacept (EVO) has shown significant progress, with over 750 patients treated, demonstrating its potential across various combinations and tumor types [4][5]. - ALX2004, the company's novel EGFR-targeted ADC, has cleared the first two dose cohorts and is currently in a phase I trial with the 4 mg/kg dose [8][19]. Market Data and Key Metrics Changes - The company anticipates that approximately half of the patients in the ASPEN-09-Breast study will be CD47 high, based on previous studies indicating a consistent percentage across different tumor types [48][49]. Company Strategy and Development Direction - The company aims to advance both Evorpacept and ALX2004 to a stage ready for pivotal studies by the end of next year, focusing on execution and robust data readouts over the next 12-18 months [4][9]. - A CD47 biomarker-driven approach is being developed to enable targeted patient selection, with plans for a companion diagnostic for CD47 expression [18][19]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential of Evorpacept to provide substantial benefits in metastatic breast cancer patients, particularly in the post-ENHERTU setting [18][19]. - The company is optimistic about the strong investigator interest in the ASPEN-09 study and expects to share meaningful efficacy and safety data by mid-2027 [19][36]. Other Important Information - The company completed a financing round of $150 million, strengthening its balance sheet and providing sufficient funds to cover operating expenses through the first half of 2028 [24][25]. - The full biomarker analysis from the phase 1/2 trial evaluating Evorpacept in combination with panitumumab is expected to be presented at the ESMO Breast Cancer Conference in May 2026 [25]. Q&A Session Summary Question: Update on ASPEN-09-Breast study and rationale for upsizing to 120 patients - Management confirmed that the study will focus on 80 patients for full data readout in mid-next year, with the upsizing to 120 patients aimed at ensuring robust data across various subpopulations [30][31][33]. Question: Feedback from investigators on the biomarker approach - Investigators are excited about the biomarker selection strategy, which aims to identify a patient population that will benefit significantly from the therapy [35][36]. Question: Reasons for pushing out safety data for ALX2004 - The change in timeline is to ensure robust data communication, with a focus on providing meaningful updates towards the end of the year [39][40]. Question: Expected ratio of CD47 high versus low expression in ASPEN-09 - Management expects around half of the patients to be CD47 high, based on literature and previous studies [48][49]. Question: Monitoring for interstitial lung disease and skin toxicity in ALX2004 - Patients will undergo regular CT scans to monitor for ILD and skin toxicity, with a low likelihood of severe toxicity based on non-human primate studies [58][59].

Core Insights - ALX Oncology is advancing its clinical development for evorpacept and ALX2004, expecting significant data and milestones in the next 12 to 18 months [1][2][3] Evorpacept Developments - Evorpacept's biomarker strategy has been validated, indicating that CD47 overexpression predicts its activity and benefits in HER2-positive cancers [1][4] - The Phase 2 ASPEN-09 trial is currently enrolling patients to evaluate evorpacept's efficacy based on CD47 expression levels, with topline data expected by mid-2027 [1][6] - A combination of evorpacept with trastuzumab and chemotherapy achieved a 65% objective response rate in patients with retained HER2-positive gastric cancer, significantly outperforming the control [6][4] ALX2004 Progress - The Phase 1 trial for ALX2004 is ongoing, with safety data from the dose-escalation phase anticipated in the second half of 2026 [1][3] - ALX2004 has shown promising preclinical anti-tumor activity in various EGFR-expressing tumor models, with a favorable safety profile [7][1] Financial Update - The company completed a $150 million equity offering, extending its cash runway through the first half of 2028 [1][12] - Research and development expenses decreased to $17.6 million for Q4 2025, down from $23.5 million in Q4 2024, reflecting a strategic prioritization of pipeline projects [13][18] - The net loss for Q4 2025 was $22.8 million, an improvement from $29.2 million in Q4 2024, attributed to reduced R&D expenses [18][19] Corporate Changes - Barbara Klencke, M.D., has been appointed as Chief Medical Officer on a permanent basis, having served in an interim capacity since September 2025 [1][12]

Core Insights - ALX Oncology Holdings Inc. is participating in multiple upcoming biotech conferences to showcase its advancements in cancer therapies [1][2]. Group 1: Conference Participation - ALX Oncology will attend the Wells Fargo Executive Biotech Summit on February 24-25, 2026, in Lake Tahoe, CA, featuring one-on-one meetings [2]. - The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 AM EST in Boston, MA [2]. - ALX Oncology will also participate in the UBS Biotech Summit on March 10, 2026, in Miami, FL, with one-on-one meetings scheduled [2]. Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies aimed at treating cancer and improving patient survival [3]. - The lead therapeutic candidate, evorpacept, is being evaluated in multiple clinical trials across various cancer indications and is positioned as a potential cornerstone therapy in immuno-oncology [3]. - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate currently undergoing a Phase 1 dose-escalation trial for patients with EGFR-expressing solid tumors [3].

Core Insights - ALX Oncology Holdings Inc. plans to report its fourth quarter and full year 2025 financial results on February 27, 2026, before market open [1] - The company will host a teleconference to discuss the financial results [1] Financial Results Webcast Information - The webcast is scheduled for February 27, 2026, at 5:30 AM PT / 8:30 AM ET [2] - Access to the conference call can be obtained by dialing 1-877-407-0755 or +1-201-389-0913 [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment [4] - The lead candidate, evorpacept, is being evaluated in multiple clinical trials across various cancer indications [4] - The second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate currently in a Phase 1 trial for EGFR-expressing solid tumors [4]

Core Viewpoint - ALX Oncology Holdings Inc. has announced the pricing of an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $150 million to support its clinical development programs and general corporate purposes [1][3]. Group 1: Offering Details - ALX Oncology is selling 76,979,112 shares of common stock at an offering price of $1.57 per share and pre-funded warrants to purchase 18,574,120 shares at $1.569 each [1]. - The gross proceeds from the offering are expected to be around $150 million before deducting underwriting discounts and commissions [1]. - The offering is expected to close on or about February 2, 2026, subject to customary closing conditions [1]. Group 2: Investors and Participation - The financing is led by new investors RA Capital Management and TCGX, with participation from various other investors including 5AM Ventures, Blackstone Multi-Asset Investing, and others [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be used to fund the continued clinical development of evorpacept and the ALX2004 program, as well as for working capital and other general corporate purposes [3]. Group 4: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with its lead candidate evorpacept currently in multiple clinical trials [6]. - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate undergoing a Phase 1 dose-escalation trial in patients with EGFR-expressing solid tumors [6].

Core Insights - ALX Oncology announced new data from a Phase 1b/2 clinical trial evaluating the CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® for metastatic breast cancer, reinforcing CD47 as a predictive biomarker for treatment response [1][2] Group 1: Clinical Trial Findings - The Phase 1b/2 trial demonstrated promising anti-tumor activity and a manageable safety profile in heavily pretreated HER2-positive breast cancer patients, with a median of six prior therapies [2] - The combination treatment achieved a confirmed objective response rate (cORR) of 56% (5 out of 9 patients) and a median progression-free survival (mPFS) of 7.4 months [2] - Additional exploratory analysis indicated that responses were largely restricted to patients with higher CD47 expression, supporting findings from the ASPEN-06 trial [3] Group 2: Future Directions - The company plans to adopt a biomarker-driven approach for patient selection in future trials involving evorpacept and HER2-targeted agents [2] - Full biomarker analysis from the Phase 1b/2 trial has been submitted for presentation at an upcoming scientific congress [4] Group 3: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with evorpacept as a lead candidate [5] - The company is also advancing a second pipeline candidate, ALX2004, which is currently in a Phase 1 trial for EGFR-expressing solid tumors [5]

Core Insights - ALX Oncology announced new data from a Phase 1b/2 clinical trial evaluating the investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® for metastatic breast cancer, reinforcing CD47 as a predictive biomarker for treatment response [1][2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with its lead candidate evorpacept showing potential as a cornerstone therapy in immuno-oncology [5] Clinical Trial Findings - The Phase 1b/2 trial demonstrated promising anti-tumor activity and a manageable safety profile, with a confirmed objective response rate of 56% and a median progression-free survival of 7.4 months in heavily pretreated HER2-positive breast cancer patients [2][3] - Additional exploratory analysis indicated that responses were primarily observed in patients with higher CD47 expression, supporting the predictive biomarker role of CD47 [3] Future Directions - The company plans to adopt a biomarker-driven approach for patient selection in future trials, particularly for combinations of evorpacept with HER2-targeted agents, and is confident in the ongoing ASPEN-09-Breast Phase 2 trial [2]

Core Insights - ALX Oncology has had a significant year, with seven different data sets read out, indicating strong progress in its clinical programs [2] - The company is focused on developing two clinical stage programs, evorpacept and ALX2004, which are differentiated within their class [2] - Evorpacept targets CD47, a crucial element in the immune system and oncology, which has historically been challenging to address [2]